Beating T-Cell Exhaustion: The Future of Myeloma Care | Marta Chesi & Erin Meermeier |

Martha Chesi and Erin Meermeier from Mayo Clinic discuss their preclinical research aimed at improving the effectiveness of bispecific antibody therapy for multiple myeloma patients who develop resistance. Their findings suggest that combining bispecific antibodies with CELMoD drugs or cytoxin can reduce T-cell exhaustion, boost immune responses, and potentially enhance long-term outcomes by preventing relapse.

Link to ASH playlist: https://healthtree.org/blood-cancer/u...

ASH Abstract: Combination with Cytotoxic Therapy and Checkpoint Blockade Overcomes Primary Resistance to BCMA Bispecific Antibody Therapy and Leads to Durable Remission of Vk*MYC Multiple Myeloma
#ASH24 #myeloma #mmsm

Follow HealthTree:
https://linktr.ee/HealthTreeUniversity
twitter.com/healthtreeformm
facebook.com/healthtreeformultiplemyeloma
instragram.com/healthtreeformultiplemyeloma